Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Trial Details

NCT ID
NCT07745361
Phase
PHASE2
Sponsor
Monte Rosa Therapeutics, Inc
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Oral MRT-2359
  • Apalutamide
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Newport Beach, California, United States|33.61891,-117.92895
  • Colorado Springs, Colorado, United States|38.83388,-104.82136
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • Age \> 18 years
  • A predicted life expectancy of ≥ 3 months and an ECOG performance status ≤ 1
  • Have histologically or cytologically confirmed castration-resistant adenocarcinoma of the prostate without small cell histology and with androgen r…
  • Have not had prior treatment with more than 1 prior taxane-based chemotherapy regimen for castration-resistant prostate cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →